Mar 22 |
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
Mar 6 |
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
|
Mar 5 |
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
|
Mar 5 |
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
|
Mar 5 |
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
|
Mar 5 |
Q4 2023 Nektar Therapeutics Earnings Call
|
Mar 5 |
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
|
Mar 4 |
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 4 |
Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
|
Mar 4 |
Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M
|